EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application memantine hydrochloride ER capsules, 7mg, 14mg, 21mg, and 28mg. Aurobindo Pharma’s memantine hydrochloride ER capsules, 7mg, 14mg, 21mg, and 28mg, are an AB-rated generic equivalent to the reference listed drug (RLD), Namenda XR of Forest Laboratories LLC. 

Memantine hydrochloride ER capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. 

Memantine hydrochloride ER capsules has an estimated market size of US $46.6 Million for the twelve months ending June 2021, as per IQVIA.